131 related articles for article (PubMed ID: 18062726)
21. Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis).
Rusconi S; Gianotti N; Adorni F; Boeri E; Menzo S; Gonnelli A; Micheli V; Meraviglia P; Trezzi M; Paolini E; Giacometti A; Corsi P; Di Pietro M; Monno L; Punzi G; Zazzi M;
J Acquir Immune Defic Syndr; 2007 Nov; 46(3):373-5. PubMed ID: 18090302
[No Abstract] [Full Text] [Related]
22. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Ghosh AK; Dawson ZL; Mitsuya H
Bioorg Med Chem; 2007 Dec; 15(24):7576-80. PubMed ID: 17900913
[TBL] [Abstract][Full Text] [Related]
23. Darunavir: in the treatment of HIV-1 infection.
Fenton C; Perry CM
Drugs; 2007; 67(18):2791-801. PubMed ID: 18062724
[TBL] [Abstract][Full Text] [Related]
24. TMC114 approved for resistant patients.
AIDS Patient Care STDS; 2006 Oct; 20(10):731. PubMed ID: 17052143
[No Abstract] [Full Text] [Related]
25. Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.
Vidal JE; Freitas AC; Song AT; Campos SV; Dalben M; Hernandez AV
Braz J Infect Dis; 2011; 15(3):245-8. PubMed ID: 21670925
[TBL] [Abstract][Full Text] [Related]
26. Darunavir (TMC114): a new HIV-1 protease inhibitor.
Molina JM; Hill A
Expert Opin Pharmacother; 2007 Aug; 8(12):1951-64. PubMed ID: 17696796
[TBL] [Abstract][Full Text] [Related]
27. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
Pernas B; Grandal M; Tabernilla A; Cid P; Pértega S; Castro-Iglesias Á; Mena Á; Margusino L; Pedreira JD; Poveda E
J Med Virol; 2016 Dec; 88(12):2125-2131. PubMed ID: 27218208
[TBL] [Abstract][Full Text] [Related]
28. Resistance profile of darunavir: combined 24-week results from the POWER trials.
de Meyer S; Vangeneugden T; van Baelen B; de Paepe E; van Marck H; Picchio G; Lefebvre E; de Béthune MP
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):379-88. PubMed ID: 18327986
[TBL] [Abstract][Full Text] [Related]
29. [Long-term virus suppression. Expanding therapy options with protease inhibitor].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():68-9. PubMed ID: 16385882
[No Abstract] [Full Text] [Related]
30. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
[No Abstract] [Full Text] [Related]
31. Darunavir: an effective protease inhibitor for HIV-infected patients.
Phung BC; Yeni P
Expert Rev Anti Infect Ther; 2011 Jun; 9(6):631-43. PubMed ID: 21692667
[TBL] [Abstract][Full Text] [Related]
32. Darunavir (Prezista) for HIV infection.
Med Lett Drugs Ther; 2006 Sep; 48(1243):74-5. PubMed ID: 16977286
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.
Young J; Scherrer AU; Günthard HF; Opravil M; Yerly S; Böni J; Rickenbach M; Fux CA; Cavassini M; Bernasconi E; Vernazza P; Hirschel B; Battegay M; Bucher HC;
HIV Med; 2011 May; 12(5):299-307. PubMed ID: 20955357
[TBL] [Abstract][Full Text] [Related]
35. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
Descamps D; Lambert-Niclot S; Marcelin AG; Peytavin G; Roquebert B; Katlama C; Yeni P; Felices M; Calvez V; Brun-Vézinet F
J Antimicrob Chemother; 2009 Mar; 63(3):585-92. PubMed ID: 19147519
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
[TBL] [Abstract][Full Text] [Related]
37. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
[TBL] [Abstract][Full Text] [Related]
38. Darunavir/ritonavir monotherapy in clinical practice.
Parienti JJ
AIDS; 2011 Jan; 25(1):119. PubMed ID: 21119326
[No Abstract] [Full Text] [Related]
39. Darunavir: a nonpeptidic antiretroviral protease inhibitor.
McCoy C
Clin Ther; 2007 Aug; 29(8):1559-76. PubMed ID: 17919539
[TBL] [Abstract][Full Text] [Related]
40. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
